As of press time, the three major indexes of Hong Kong stocks fell, the Hang Seng index fell 3.47% to 21139.88 points, with a turnover of 86.882 billion; the state-owned enterprises index fell 3.32% to 7430.09 points, with a turnover of 36.542 billion; and the red chip index fell 1.77% to 4101.58 points, with a turnover of 4.68 billion.

Aluminum stocks rose against the market, of which Rusal soared nearly 21%, temporarily recorded three Lianyang, Chinalco rose more than 3%, Rongyang Industry and China Hongqiao rose about 2%;

Gold stocks rose, Zhaojin Mining rose more than 15%, China Gold International rose 9.07%, Lingbao Gold rose nearly 7%, Shandong Gold rose more than 5%;

Hong Kong tech stocks, which tumbled at the start of the session, rose in the short term, while the Hang Seng technology index narrowed its decline to 3.65 per cent after falling nearly 6 per cent at one point. Among the constituent stocks, the decline of Tencent narrowed to 3% and Alibaba narrowed to 1.5%, all of which fell more than 5%.

Hong Kong banking stocks fell collectively, including Standard Chartered Group down 6%, HSBC Holdings down 5%, Bank of China Hong Kong down 3.46%, Hang Seng Bank down 2.5%;

Education stocks fell sharply, thinking music education fell by more than 13%, maple leaf education fell by 11.9%, and Guangzheng education fell by 10%.

Hot stocks

Gusheng Hall was included in the Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect, effective today, rising 1.06% to HK $42.9 in intraday trading.

At one point, Vivia rose more than 5%, but now the increase has narrowed to more than 1% to HK $2.66. the company expects revenue of 2 billion yuan in 2021, an increase of more than 180% over the same period last year.

Minimally invasive Medical fell 8.35% to HK $18.50, and its share price hit a new low of more than a year and a half. The company issued a profit warning and expected a loss of US $2.75 to US $285 million in 2021, compared with a loss of US $191 million in 2020.

After the performance of Hutchison Medicine, it fell sharply for two consecutive days and is now down more than 10% to HK $31.3, continuing to hit an all-time low. Analysts said that Hutchison has so far approved three innovative drugs on the market, namely, Sovantinib, fuquitinib and Sevotinib. During the reporting period, R & D investment and sales expenditure increased significantly, resulting in serious losses of the company.